NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

Neurology International is a prestigious open-access journal published by MDPI that has been making significant contributions to the field of neurology since its establishment in 2009. With its ISSN 2035-8377, this journal is committed to disseminating high-quality, peer-reviewed research that addresses a wide range of clinical topics in neurology. Operating out of Basel, Switzerland, the journal holds a respectable Q2 ranking in the clinical neurology category as of 2023, indicating its influence and dedication to advancing scientific knowledge. Researchers and practitioners alike will find value in its comprehensive articles, which are readily accessible to a global audience, facilitating the sharing of innovative findings and clinical practices. As it converges towards 2024, Neurology International continues to provide a vital platform for scholarly discourse, aiming to improve patient outcomes and enhance our understanding of neurological disorders.

Frontiers in Neurology is a premier open-access journal dedicated to the advancement of research in the field of neurology, published by FRONTIERS MEDIA SA since 2010. With the ISSN 1664-2295 and an international reach established from its base in Lausanne, Switzerland, this journal has rapidly become a vital resource for neurologists and neuroscientists alike, presenting high-quality research that addresses critical developments in clinical and experimental neurology. Holding a solid Q2 quartile ranking in both neurology and clinical neurology, Frontiers in Neurology demonstrates substantial influence, evidenced by its respectable Scopus rankings—151st in clinical neurology and 77th in neuroscience neurology. The journal employs robust peer review practices to ensure rigor and integrity, while its open-access model fosters widespread dissemination of knowledge. By facilitating interdisciplinary dialogue and empowering research efforts, this journal not only supports the academic community but also contributes to the advancement of treatment and understanding of neurological disorders.

Neurological Sciences and Neurophysiology, published by Wolters Kluwer Medknow Publications, serves as a pivotal platform for dissemination and discussion of recent advancements and research in the fields of neurology and neurophysiology. Since its transition to an Open Access format in 2020, this journal aims to enhance accessibility to crucial developments in neurological sciences for researchers, professionals, and students alike. With an ISSN of 2636-865X, it seeks to bridge the gap between clinical practice and experimental science, promoting innovative approaches to neurological disorders. While currently ranked in the Q4 quartile in the Neurology category, the journal is committed to improving its standing through rigorous peer review and publication of high-quality research. The journal's scope encompasses a wide range of topics, ensuring that it appeals to a diverse audience, while its Scopus ranks indicate its emerging presence in the global scientific community. Located in Mumbai, India, the journal welcomes contributions that push the boundaries of our understanding of the nervous system, making it a vital resource for scholars in this dynamic field.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

The Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.

Journal of Molecular Neuroscience, published by SpringerNature, is a critical resource for researchers and professionals in the dynamic field of neuroscience. With ISSN 0895-8696 and E-ISSN 1559-1166, this journal has established itself as a key player since its inception in 1989, covering a range of topics within Cellular and Molecular Neuroscience and Medicine (miscellaneous). Its impressive rankings, including being placed in the Q2 quartile for Medicine and Q3 for Cellular and Molecular Neuroscience, underscore its scholarly impact, featuring innovative research that informs and advances our understanding of neural processes. The journal does not currently operate under an open-access model, providing rich, peer-reviewed content geared towards academics and professionals seeking comprehensive analyses and breakthroughs in molecular neurobiology. With a publication window extending to 2024, the Journal of Molecular Neuroscience remains dedicated to enhancing the scientific community's knowledge landscape, making it an essential reference for those passionate about unraveling the complexities of the nervous system.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

INFLAMMOPHARMACOLOGY is a premier journal published by SPRINGER BASEL AG, specializing in the evolving fields of immunology and pharmacology. Established in 1991, the journal has made significant strides in contributing to the understanding of inflammation-related disorders, therapeutic innovations, and the pharmacological implications associated with these conditions. With an impressive Q2 ranking in Immunology and Q1 rankings in both Pharmacology and Medical Pharmacology for 2023, alongside notable Scopus rankings, INFLAMMOPHARMACOLOGY maintains its position at the forefront of scientific research. The journal provides a vital platform for researchers and practitioners to disseminate groundbreaking findings and explore novel approaches in therapeutics, reinforcing the importance of evidence-based medicine. Accessible exclusively through traditional subscription options, it continues to attract a diverse readership invested in advancing knowledge within these cutting-edge disciplines.